BioVie Inc. Files 8-K/A Amendment
Ticker: BIVIW · Form: 8-K/A · Filed: Mar 4, 2024 · CIK: 1580149
| Field | Detail |
|---|---|
| Company | Biovie Inc. (BIVIW) |
| Form Type | 8-K/A |
| Filed Date | Mar 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $1.00, $0.9999 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
TL;DR
BioVie Inc. filed an 8-K/A amendment on March 4, 2024, for financial statements/exhibits.
AI Summary
BioVie Inc. filed an amendment (8-K/A) on March 4, 2024, to its current report. This filing pertains to financial statements and exhibits, indicating a potential update or correction to previously submitted information. The company, formerly known as NanoAntibiotics, Inc., is incorporated in Nevada and operates in the Pharmaceutical Preparations sector.
Why It Matters
This amendment suggests BioVie Inc. is updating or correcting previously filed financial statements or exhibits, which could be important for investors assessing the company's financial health.
Risk Assessment
Risk Level: low — This filing is an amendment to a previous report and does not introduce new material events or financial disclosures.
Key Players & Entities
- BioVie Inc. (company) — Registrant
- NanoAntibiotics, Inc. (company) — Former company name
- March 4, 2024 (date) — Filing date
FAQ
What is the purpose of this 8-K/A filing by BioVie Inc.?
The 8-K/A filing on March 4, 2024, is an amendment to a previous report, specifically concerning Financial Statements and Exhibits.
When was this amendment filed?
The amendment was filed on March 4, 2024.
What was BioVie Inc.'s former name?
BioVie Inc.'s former name was NanoAntibiotics, Inc.
In which state is BioVie Inc. incorporated?
BioVie Inc. is incorporated in Nevada.
What is BioVie Inc.'s primary business sector?
BioVie Inc. operates in the Pharmaceutical Preparations sector (SIC code 2834).
Filing Stats: 620 words · 2 min read · ~2 pages · Grade level 8.1 · Accepted 2024-03-04 17:28:48
Key Financial Figures
- $0.0001 — tered Class A Common Stock, par value $0.0001 per share BIVI The Nasdaq Stock Marke
- $1.00 — blic offering price to the Investors of $1.00 per share and/or pre-funded warrants to
- $0.9999 — blic offering price to the Investors of $0.9999 per Pre-Funded Warrant, together with c
Filing Documents
- bivi-20240304_8ka1.htm (8-K/A) — 27KB
- bivi-20240304_ex5z1.htm (EX-5.1) — 22KB
- bivi-20240304_ex5z2.htm (EX-5.2) — 16KB
- image_001.jpg (GRAPHIC) — 17KB
- image_002.jpg (GRAPHIC) — 51KB
- image_003.jpg (GRAPHIC) — 15KB
- image_004.jpg (GRAPHIC) — 57KB
- image_006.jpg (GRAPHIC) — 8KB
- image_005.jpg (GRAPHIC) — 8KB
- 0001520138-24-000092.txt ( ) — 464KB
- bivi-20240304.xsd (EX-101.SCH) — 3KB
- bivi-20240304_lab.xml (EX-101.LAB) — 33KB
- bivi-20240304_pre.xml (EX-101.PRE) — 22KB
- bivi-20240304_8ka1_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 5.1 Opinion of Sherman & Howard L.L.C. 5.2 Opinion of Reed Smith LLP 10.1* Placement Agent Agreement, dated as of March 4, 2024 by and between the Company and the Placement Agent. 23.1 Consent of Sherman & Howard L.L.C. (included in Exhibit 5.1). 23.2 Consent of Reed Smith LLP (included in Exhibit 5.2). 99.1* Press Release dated March 1, 2024. 99.2* Press Release dated March 4, 2024. * Previously filed as an exhibit to the Original 8-K.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 4, 2024 BIOVIE INC. By: /s/ Joanne Wendy Kim Name: Joanne Wendy Kim Title: Chief Financial Officer